You're 100% correct Jess, You and I have said that all along, This should have just transferred to OTCBB in the first place, .40's, There you are correct too, Sorry to say, What a POS this has turned out for us, Take care
That deal can come at any time, You may hear a mention of it on Sept 9 - 10 investors forums in NY, Just too many things going on with this company to concentrate on one issue, you've got GlaxoSmithKline, Novartis , CVac, Working With Chinese company Israeli-Palestinian company , At any day something could send this company flying, May be weeks or months, But it is coming IMO,
I agree, 80 pct of all the post on this board belong to bashers, How I know is, Thats how many post I cant view, They are all on Iggy, Thats the best feature on Yahoo.
IMO this may turn out to be one of the best stocks i've ever owned.
Yesterday I picked up PRAN another Aussie stock, I've owned it in the past and made a bundle on it. G/L
Problem is J, who knows where the price will be if there's no nasdaq compliance, that news could cut the price in 1/2 again, which in turn will bring in a new crop of buyers at a much much lower price then all of us paid, And once the price goes up, They'll sell for a nice profit and leave us no better off then today's price. I've said many times that IMO there will be no major money made from the Automated sales till mid 2016, This company has basically screwed all their investors.
I kind of agree with you Jess, What would be the advantage of holding on to that news if compliance was given, I can't figure out why holding on to that news would in any way help them,But I'm sure Eric will find some way to spin this as a positive on stocktwits, take care jess
I think for anyone getting in here or lower, They should be golden , The ones that are pre split are gonna have a hard time, This company has IMO been screwing investors all along just to line their own pockets, I may be wrong, But I dont think so.
Ive said before that I dont think there will be any bankable $$$$ from the automated test till mid 2016, But who knows, They may surprise us, LOL
I also think that Abbott is putting the screws to BGMD , It looks like they're making BG foot part of the bill to get this started, Where as I had thought they were going to take care of everything, The other question is. Whats going on with #2 - 501K submission ????
Also if this runs into mid 2016 BG will be looking for more cash, RE; dilution again
Take care jess
You have that backwards there my friend.
If a company closes below a $1/share bid price for 30 consecutive days, the Nasdaq sends the company a written notice. The notice states that the company is no longer in compliance with its continued listing requirements and has 180 days to regain compliance. Otherwise, the company will face delisting.
the company has 180 calendar days to regain compliance. In that time frame, if the company closes at or above a $1/share bid price for ten consecutive days, the Nasdaq will inform the company that it has regained compliance, and close the issue. So, the matter then becomes raising the share price (every stock's ultimate goal). There are a few ways a company can do this:
MW: Prima BioMed Ltd. (PBMD:NASDAQ; PRR:ASX) is an Australian immunotherapy company by origin, and listed on NASDAQ. It is active in immunotherapy with a broad pipeline aimed at developing therapies for several types of cancer and autoimmune disease. Next to its proprietary LAG-3 platform, its lead product is CVac, an autologous, dendritic cell-based cancer vaccine that’s in clinical trials for ovarian cancer. The company recently released positive Phase 2 results that showed a clear overall survival benefit in second-remission patients with ovarian cancer. I feel these results will trigger a potential partnership with big pharma to start with a Phase 3 trial.
TLSR: What should make CVac interesting to investors, in addition to its fast-track and orphan drug status with the FDA?
MW: Prima BioMed’s CVac is a good example of a successful immunotherapy, a therapy that has come a long way in recent years and is now on the brink of becoming a key player in oncology. We expect a partnership with a large pharmaceutical company in the near future. So far, the company has financed the development of CVac all by itself.
“The big chunk of the healthcare sector’s overall growth is coming from subsectors like biotechnology.”
Next to that, LAG-3 is an increasingly important immuno-oncology target, which is dominated by Prima BioMed. LAG-3 possibly has the ability to activate the immune system to kill cancer cells. When you look at the immunotherapy field, there are quite a lot of products already on the market and in development. I think that immunotherapy is the most important field of cancer drug development today.
Most advanced immune therapy under LAG-3 is IMP321, a soluble LAG-3 therapy. In cancer patients, IMP321 showed it could, in combination with chemotherapy in Phase 2a, double the clinical response rate compared to chemo alone.
You're right on the $1.00 issue jess, that would give them the 180 days to stay listed, question is on the 2.5M Issue, IMHO they should have passed that too, With the cash and warrants they have it should push it over that mark, at least for enough time to satisfy nasdaq for the time being.
- Shares on issue: ASX: PRR, 1.97 billion
- Listed options on issue: ASX: PRRO, 77.4 million (3.9% of current issued capital), exercisable at 20 cent by 19 June 2017
- Unlisted options: 530.2 million (26.9% of current issued capital), average exercise price 3.18 cents (AUD), average expiry date 13 March 2020
- Turnover: ASX, 6.8 million shares per day; Nasdaq, 1,339,000 ADRs per day (last 12 months average)
- ISIN: US745154B2034
- Share ratio for ADRs traded on Nasdaq: 1:30 (Depositary is BNY Mellon, Nasdaq: PBMD)
- ADRs outstanding as at 17 August 2015: 18.8 million (28.5% of capital))
- ADRs potentially available for trade on Nasdaq: 65.8 million
- Registered shareholders as at July 2015- ~12,100
- Substantial shareholders (ie 5%): Ridgeback Capital Management (5.7%)
March 14 2015 15M raised from Ridgeback
March 31 2015 2.4M on hand
June 11 2015 237K from rebate france
July 31 2015 10M raised from shareholders
Aug 14 2015 over 1M Milestone payment from NOVARTIS
Yet to come, Partner to finish developement of CVac, $$$$$$$$ With that
More milestone payments from GlaxoSmithKline, Novartis
Also Partners include - Eddingham - Neopharm.
Enough cash till Q4 2016
Not only that, I think we may have more NEWS before Q4 2016, What do you think !!!! LOL
THE TIMES THEY ARE A CHANGING